Company intelligence / Profile preview
Aquinnah Pharmaceuticals
Cambridge, Massachusetts, United Statesaquinnahpharma.com ↗
- Ownership
- Private
- Employees
- ~2
- Development stage
- Other
01
Overview
Aquinnah has demonstrated preclinical efficacy for its lead oral small molecule targeting tau-stress granule interactions in advanced animal models of Alzheimer’s disease, showing ~70% reduction in pathological tau. The compound is designed as a once-daily pill with potential to combine with anti-amyloid drugs. ALS programs target TDP-43 pathology using similar approaches. No clinical trial results yet; most programs are preclinical or IND-enabling.
- Therapeutic areas
- Neurology
- Modalities
- small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Roche – collaboration to advance brain penetrant oral small molecules for ALS and neurodegenerative diseases; previously partnered with Pfizer on investment/funding
Beyond the preview
Go deeper on Aquinnah Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aquinnah Pharmaceuticals.